
    
      The primary objective of this phase 2 study is to assess objective response rate of SHR-1210
      in patients with relapsed or refractory classic Hodgkin's lymphoma. The secondary objective
      is to observe the duration of response,progression free survival,time to response,overall
      survival and safety of SHR-1210 in relapsed or refractory classic Hodgkin's
      lymphoma.Pharmacokinetic index is also investigated in 12 patients.
    
  